We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2
Read MoreHide Full Article
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) reported encouraging preliminary sales figure for its lead drug, Exparel.
Preliminary numbers for Exparel sales came at $80.4 million for the second quarter of 2018, rising approximately 15% year over year. The company reported that daily sales grew 11%, 16% and 18% for the month of April, May, and June, respectively, compared with the year-ago period.
Growth in drug sales can primarily be attributed to expanding adoption of Exparel as a non-opioid pain management therapy in various surgical procedures.
The Zacks Consensus Estimate for total sales, which includes collaborative licensing and milestone revenues, and royalty revenues along with Exparel sales, for the second quarter is pegged at $77.31 million. The preliminary results already suggest a revenue beat.
Pacira’s share price has increased 10.8% so far beginning April 2018, compared with the industry’s gain of 2.9%.
We remind investors that the FDA has approved the label expansion of Exparel to include administration via nerve block for prolonged regional analgesia, earlier in April. Pacira, along with its partner Johnson & Johnson (JNJ - Free Report) is focusing on the launch of Exparel in the expanded indication.
Meanwhile in June, Pacira inked an agreement with China-based Nuance for the development and commercialization of Exparel in China. Per the agreement, Pacira will receive $3 million in upfront payment upon closing of the transaction and will be eligible for additional $55 million in regulatory and sales milestone payments.
Pacira is developing Exparel for its use as pain management post spinal fusion and various other surgeries and expanding its label in pediatric patients.
Estimates for AcelRx’s loss have narrowed 4.4% for 2018 and 15.3% for 2019 in the past 60 days. The stock has surged 77.8% year to date.
Estimates for CollPlant’s loss have narrowed 1.7% for 2018 and 1.4% for 2019 over the past 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) reported encouraging preliminary sales figure for its lead drug, Exparel.
Preliminary numbers for Exparel sales came at $80.4 million for the second quarter of 2018, rising approximately 15% year over year. The company reported that daily sales grew 11%, 16% and 18% for the month of April, May, and June, respectively, compared with the year-ago period.
Growth in drug sales can primarily be attributed to expanding adoption of Exparel as a non-opioid pain management therapy in various surgical procedures.
The Zacks Consensus Estimate for total sales, which includes collaborative licensing and milestone revenues, and royalty revenues along with Exparel sales, for the second quarter is pegged at $77.31 million. The preliminary results already suggest a revenue beat.
Pacira’s share price has increased 10.8% so far beginning April 2018, compared with the industry’s gain of 2.9%.
We remind investors that the FDA has approved the label expansion of Exparel to include administration via nerve block for prolonged regional analgesia, earlier in April. Pacira, along with its partner Johnson & Johnson (JNJ - Free Report) is focusing on the launch of Exparel in the expanded indication.
Meanwhile in June, Pacira inked an agreement with China-based Nuance for the development and commercialization of Exparel in China. Per the agreement, Pacira will receive $3 million in upfront payment upon closing of the transaction and will be eligible for additional $55 million in regulatory and sales milestone payments.
Pacira is developing Exparel for its use as pain management post spinal fusion and various other surgeries and expanding its label in pediatric patients.
Pacira Pharmaceuticals, Inc. Price
Pacira Pharmaceuticals, Inc. Price | Pacira Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Pacira currently carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the same sector include AcelRx Pharmaceuticals, Inc. and CollPlant Holdings Ltd. (CLGN - Free Report) , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Estimates for AcelRx’s loss have narrowed 4.4% for 2018 and 15.3% for 2019 in the past 60 days. The stock has surged 77.8% year to date.
Estimates for CollPlant’s loss have narrowed 1.7% for 2018 and 1.4% for 2019 over the past 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>